Aspen Pharmacare Holdings Ltd - Asset Resilience Ratio
Aspen Pharmacare Holdings Ltd (APN) has an Asset Resilience Ratio of 6.67% as of December 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Aspen Pharmacare Holdings Ltd (APN) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2022)
This chart shows how Aspen Pharmacare Holdings Ltd's Asset Resilience Ratio has changed over time. See Aspen Pharmacare Holdings Ltd (APN) net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Aspen Pharmacare Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see APN stock market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ZAC8.04 Billion | 6.67% |
| Short-term Investments | ZAC0.00 | 0% |
| Total Liquid Assets | ZAC8.04 Billion | 6.67% |
Asset Resilience Insights
- Limited Liquidity: Aspen Pharmacare Holdings Ltd maintains only 6.67% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Aspen Pharmacare Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Aspen Pharmacare Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 1.96% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317 |
Drug Manufacturers - Specialty & Generic | 6.62% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 8.47% |
Annual Asset Resilience Ratio for Aspen Pharmacare Holdings Ltd (2010–2022)
The table below shows the annual Asset Resilience Ratio data for Aspen Pharmacare Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-06-30 | 0.29% | ZAC318.00 Million ≈ $169.00K |
ZAC111.38 Billion ≈ $59.19 Million |
+0.28pp |
| 2021-06-30 | 0.01% | ZAC9.00 Million ≈ $4.78K |
ZAC109.68 Billion ≈ $58.29 Million |
+0.00pp |
| 2020-06-30 | 0.00% | ZAC6.00 Million ≈ $3.19K |
ZAC133.17 Billion ≈ $70.77 Million |
+0.00pp |
| 2019-06-30 | 0.00% | ZAC2.00 Million ≈ $1.06K |
ZAC122.32 Billion ≈ $65.00 Million |
+0.71pp |
| 2018-06-30 | -0.71% | ZAC-940.00 Million ≈ $-499.56K |
ZAC132.84 Billion ≈ $70.60 Million |
-9.92pp |
| 2017-06-30 | 9.21% | ZAC10.71 Billion ≈ $5.69 Million |
ZAC116.30 Billion ≈ $61.81 Million |
+9.17pp |
| 2015-06-30 | 0.03% | ZAC30.20 Million ≈ $16.05K |
ZAC88.42 Billion ≈ $46.99 Million |
+0.03pp |
| 2010-06-30 | 0.00% | ZAC100.00K ≈ $53.14 |
ZAC19.80 Billion ≈ $10.52 Million |
-- |
About Aspen Pharmacare Holdings Ltd
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and markets specialty and branded pharmaceutical products in Africa, the Middle East, the Americas, Europe CIS, Australasia, and Asia. It operates through Commercial Pharmaceuticals and Manufacturing segments. The company offers injectables for therapeutic areas, such as anaesthetics, anticoagulants, antithrombotic ag… Read more